Business
Ludwig Enterprises Develops Program to Support Ketamine Clinics
Ludwig Enterprises Develops Program to Support Ketamine Clinics.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"SPARKS, NV / ACCESSWIRE / March 7, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company's newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with Treatment Resistant Depression. Drs. Farahay and Lee are finalizing plans to open a Ketamine clinic in southeastern Ohio in 2023."Major depressive disorder is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide," said Dr. Marvin S. Hausman, MD, Chief Medical Officer of Ludwig Enterprises, and creator of the mRNA Inflammatory Index™. "Our mRNA Inflammatory Index could become a reliable and reproducible biomarker guide to patient treatment selection, evaluation of ketamine dosage used and therapeutic response."Ketamine is a pharmaceutical discovered over 60 years ago originally approved by the FDA as an anesthetic and analgesic. It was first used psychotherapeutically and for post operative pain in 1974. It was added to the WHO's list of Essential Medicines in 1985. Studies in the early 2000s found Ketamine to be effective in fighting depression resistant to other treatments."The ketamine clinic industry is growing rapidly," said Dr. Jeff Lee, the clinic's co-founder. "Our partnership with Ludwig - The Genomics Language Company™ will provide artificial intelligence (AI) to track mRNA inflammatory markers in patients with treatment resistant depression who are undergoing Ketamine therapy, which would be a huge breakthrough for the industry. This statistical analytical approach will assist in substantiating the patient's subjective reporting experience and may allow adjustment of treatment dosage."About Ludwig Enterprises, Inc.Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabete...